Form 8-K - Current report:
SEC Accession No. 0001193125-25-052013
Filing Date
2025-03-11
Accepted
2025-03-11 16:58:36
Documents
19
Period of Report
2025-03-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d939908d8k.htm   iXBRL 8-K 29506
2 EX-1.1 d939908dex11.htm EX-1.1 202217
3 EX-5.1 d939908dex51.htm EX-5.1 39638
7 GRAPHIC g939908g0311053630699.jpg GRAPHIC 2088
8 GRAPHIC g939908g16q46.jpg GRAPHIC 3011
9 GRAPHIC g939908g38v82.jpg GRAPHIC 18130
10 GRAPHIC g939908g75l27.jpg GRAPHIC 4612
  Complete submission text file 0001193125-25-052013.txt   503743

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mura-20250311.xsd EX-101.SCH 2869
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mura-20250311_lab.xml EX-101.LAB 17911
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mura-20250311_pre.xml EX-101.PRE 11247
21 EXTRACTED XBRL INSTANCE DOCUMENT d939908d8k_htm.xml XML 3610
Mailing Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380
Business Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 353 1 905 8020
Mural Oncology plc (Filer) CIK: 0001971543 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41837 | Film No.: 25728427
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)